Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 1Q

Total revenue in the U.S. was up 6% to $3.0 billion and outside the U.S. increased 13% to $2.5 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 1Q

1Q Revenues: $5.5 billion (+9%)

1Q Earnings: $1.2 billion (-5%)

Comments:Total revenue in the U.S. was up 6% to $3.0 billion and outside the U.S. increased 13% to $2.5 billion. Zyprexa sales were $1.2 billion (+8%). Cymbalta sales were $803.2 million (+13%). Alimta sales were $527.4 million (+57%). Humalog sales were up 12% to $506.4 million. Cialis sales were $408.3 million (+14%). Gemzar sales were down 22% to $287.8 million, due to the entry of generic competition in some markets. Total revenue for the quarter includes $115.7 million of Byetta revenue and $92.4 million of Erbitux revenue. R&D expenses were $1.0 billion, or 19% of total revenue. In the quarter, the company recognized a charge of $50.0 million related to acquired in-process R&D associated with the in-licensing agreement with Acrux Ltd., and a charge of $26.2 million for restructuring costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters